Prolonged glucocorticoid treatment in ARDS: Impact on intensive care unit-acquired weakness

Frontiers in Pediatrics

Volumn 4, Issue AUG, 2016, Pages

  Meduri, Gianfranco Umberto ^a   Schwingshackl, Andreas ^b   Hermans, Greet ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acute respiratory distress syndrome; Glucocorticoid treatment; Intensive care unit acquired weakness; Mechanical ventilation; Muscle weakness; Steroids; Survival

Indexed keywords

EID: 85010782895     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2016.00069     Document Type: Short Survey

References (51)

1. Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, et al. The sick and the weak: neuropathies/myopathies in the critically ill. Physiol Rev (2015) 95:1025-109. doi:10.1152/physrev.00028.2014
2. Weber-Carstens S, Deja M, Koch S, Spranger J, Bubser F, Wernecke KD, et al. Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. Crit Care (2010) 14:R119. doi:10.1186/cc9074
3. Witteveen E, Wieske L, Verhamme C, Schultz MJ, van Schaik IN, Horn J. Muscle and nerve inflammation in intensive care unit-acquired weakness: a systematic translational review. J Neurol Sci (2014) 345:15-25. doi:10.1016/j.jns.2014.07.014
4. Langhans C, Weber-Carstens S, Schmidt F, Hamati J, Kny M, Zhu X, et al. Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy. PLoS One (2014) 9:e92048. doi:10.1371/journal.pone.0092048
5. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest (2009) 136:1631-43. doi:10.1378/chest.08-2408
6. van Hees HW, Schellekens WJ, Linkels M, Leenders F, Zoll J, Donders R, et al. Plasma from septic shock patients induces loss of muscle protein. Crit Care (2011) 15:R233. doi:10.1186/cc10475
7. Li YP, Reid MB. NF-kappa B mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol (2000) 279:R1165-70
8. Smuder AJ, Hudson MB, Nelson WB, Kavazis AN, Powers SK. Nuclear factor-kappaB signaling contributes to mechanical ventilation-induced diaphragm weakness*. Crit Care Med (2012) 40:927-34. doi:10.1097/CCM.0b013e3182374a84
9. de Jonghe B, Lacherade JC, Sharshar T, Outin H. Intensive care unit-acquired weakness: risk factors and prevention. Crit Care Med (2009) 37:S309-15. doi:10.1097/CCM.0b013e3181b6e64c
10. Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care (2015) 19:274. doi:10.1186/s13054-015-0993-7
11. Jung B, Moury PH, Mahul M, de Jong A, Galia F, Prades A, et al. Diaphragmatic dysfunction in patients with ICU-acquired weakness and its impact on extubation failure. Intensive Care Med (2015) 19:274. doi:10.1007/s00134-015-4125-2
12. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA (2002) 288:2859-67. doi:10.1001/jama.288.22.2859
13. De Jonghe B, Bastuji-Garin S, Durand MC, Malissin I, Rodrigues P, Cerf C, et al. Respiratory weakness is associated with limb weakness and delayed weaning in critical illness. Crit Care Med (2007) 35:2007-15. doi:10.1097/01.ccm.0000281450.01881.d8
14. Petrof BJ, Hussain SN. Ventilator-induced diaphragmatic dysfunction: what have we learned? Curr Opin Crit Care (2016) 22:67-72. doi:10.1097/MCC.0000000000000272
15. Fan E, Dowdy DW, Colantuoni E, Mendez-Tellez PA, Sevransky JE, Shanholtz C, et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. Crit Care Med (2014) 42:849-59. doi:10.1097/CCM.0000000000000040
16. Hermans G, Van Mechelen H, Clerckx B, Vanhullebusch T, Mesotten D, Wilmer A, et al. Acute outcomes and 1-year mortality of intensive care unit-acquired weakness. A cohort study and propensity-matched analysis. Am J Respir Crit Care Med (2014) 190:410-20. doi:10.1164/rccm.201312-2257OC
17. Patt H, Bandgar T, Lila A, Shah N. Management issues with exogenous steroid therapy. Indian J Endocrinol Metab (2013) 17:S612-7. doi:10.4103/2230-8210.123548
18. Hermans G, Wilmer A, Meersseman W, Milants I, Wouters PJ, Bobbaers H, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med (2007) 175:480-9. doi:10.1164/rccm.200605-665OC
19. Zhou T, Fan XM, Wang YQ, Qi YJ, Chen H, Qian SY. [Effects of different doses of hydrocortisone on acute lung injury in rats with early septic shock induced by Escherichia coli]. Zhonghua Er Ke Za Zhi (2004) 42:644-8
20. Kamiyama K, Matsuda N, Yamamoto S, Takano K, Takano Y, Yamazaki H, et al. Modulation of glucocorticoid receptor expression, inflammation, and cell apoptosis in septic guinea pig lungs using methylprednisolone. Am J Physiol Lung Cell Mol Physiol (2008) 295:L998-1006. doi:10.1152/ajplung.00459.2007
21. Wang XQ, Zhou X, Zhou Y, Rong L, Gao L, Xu W. Low-dose dexamethasone alleviates lipopolysaccharide-induced acute lung injury in rats and upregulates pulmonary glucocorticoid receptors. Respirology (2008) 13:772-80. doi:10.1111/j.1440-1843.2008.01344.x
22. Zhang Y, Zuo W, Rong Q, Teng G, Zhang YM. Glucocorticoid receptor expression on acute lung injury induced by endotoxin in rats. World J Emerg Med (2010) 1:65-9
23. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med (2002) 165:983-91. doi:10.1164/ajrccm.165.7.2106014
24. Seam N, Meduri GU, Wang H, Nylen ES, Sun J, Schultz MJ, et al. Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med (2012) 40:495-501. doi:10.1097/CCM.0b013e318232da5e
25. Claesson J, Freundlich M, Gunnarsson I, Laake J, Møller M, Vandvik P, et al. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand (2016) 60:697-709. doi:10.1111/aas.12713
26. Cho YJ, Moon JY, Shin ES, Kim JH, Jung H, Park SY, et al. Clinical practice guideline of acute respiratory distress syndrome. Korean J Crit Care Med (2016) 31:76-100. doi:10.4266/kjccm.2016.31.2.76
27. Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet (2016). doi:10.1016/S0140-6736(16)00578-X
28. Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care (2014) 18:R63. doi:10.1186/cc13819
29. Tang B, Craig J, Eslick G, Seppelt I, McLean A. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med (2009) 37:1594-603. doi:10.1097/CCM.0b013e3181b41b9b
30. Meduri GU. An historical review of glucocorticoid treatment in sepsis. Disease pathophysiology and the design of treatment investigation. Sepsis (1999) 3:21-38. doi:10.1023/A:1009870524359
31. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis (1988) 138:62-8. doi:10.1164/ajrccm/138.1.62
32. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med (1987) 317:1565-70. doi:10.1056/NEJM198712173172504
33. Horita N, Hashimoto S, Miyazawa N, Fujita H, Kojima R, Inoue M, et al. Impact of corticosteroids on mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Intern Med (2015) 54:1473-9. doi:10.2169/internalmedicine.54.4015
34. Annane D. Pro: the illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med (2011) 183:1125-6. doi:10.1164/rccm.201102-0345ED
35. Schwingshackl A, Meduri GU, Kimura D, Cormier SA, Anand KJ. Corticosteroids in pediatric ARDS: all cards on the table. Intensive Care Med (2015) 41:2036-37. doi:10.1007/s00134-015-4027-3
36. Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RA, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med (2016) 42:829-40. doi:10.1007/s00134-015-4095-4
37. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med (2006) 354:1671-84. doi:10.1056/NEJMoa051693
38. Meduri GU, Marik PE, Chrousos GP, Pastores SM, Arlt W, Beishuizen A, et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med (2008) 34:61-9. doi:10.1007/s00134-007-0933-3
39. Thompson BT, Ancukiewicz M, Hudson LD, Steinberg KP, Bernard GR. Steroid treatment for persistent ARDS: a word of caution. Crit Care (2007) 11:425. doi:10.1186/cc6186
40. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med (2015) 163:519-28. doi:10.7326/M15-0715
41. Hermans G, Casaer MP, Clerckx B, Guiza F, Vanhullebusch T, Derde S, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med (2013) 1:621-9. doi:10.1016/S2213-2600(13)70183-8
42. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med (2003) 348:683-93. doi:10.1056/NEJMoa022450
43. Needham DM, Wozniak AW, Hough CL, Morris PE, Dinglas VD, Jackson JC, et al. Risk factors for physical impairment after acute lung injury in a national, multicenter study. Am J Respir Crit Care Med (2014) 189:1214-24. doi:10.1164/rccm.201401-0158OC
44. Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med (2007) 33:1876-91. doi:10.1007/s00134-007-0772-2
45. Hough CL, Steinberg KP, Taylor Thompson B, Rubenfeld GD, Hudson LD. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med (2009) 35:63-8. doi:10.1007/s00134-008-1304-4
46. Bednarik J, Vondracek P, Dusek L, Moravcova E, Cundrle I. Risk factors for critical illness polyneuromyopathy. J Neurol (2005) 252:343-51. doi:10.1007/s00415-005-0654-x
47. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med (2001) 29:2281-6. doi:10.1097/00003246-200112000-00008
48. Nanas S, Kritikos K, Angelopoulos E, Siafaka A, Tsikriki S, Poriazi M, et al. Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit. Acta Neurol Scand (2008) 118:175-81. doi:10.1111/j.1600-0404.2008.00996.x
49. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev (2015) 12:CD002243. doi:10.1002/14651858.CD002243.pub3
50. Code of Federal Regulations. Title 21. In: Administration USFaD, editor. U.S. Department of Health and Human Services, Subcharter D-Drugs for Human Use. Vol. 5. Report Number 21CFR312.32 (2015). Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=312.32
51. De Jonghe B, Bastuji-Garin S, Sharshar T, Outin H, Brochard L. Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med (2004) 30:1117-21. doi:10.1007/s00134-004-2174-z